Literature DB >> 29862318

Results from implementing updated 2012 World Health Organization Guidance on early-warning indicators of HIV drug resistance in Zimbabwe.

More Mungati1,2, Mutsa Mhangara1, Janet Dzangare1, Owen Mugurungi1, Tsitsi Apollo1, Elizabeth Gonese3, Peter H Kilmarx3, Christine C Chakanyuka-Musanhu4, Gerald Shambira2, Mufuta Tshimanga2.   

Abstract

OBJECTIVE: This study evaluated the performance of sentinel sites in preventing the emergence of HIVDR using Early Warning Indicators (HIVDR EWI) survey.
METHODS: Adult and paediatric patient data on: On time pill pick up, Retention in care, Pharmacy stock-outs, and Dispensing practices was collected. Information from pharmacy registers was verified using facility-held cards. This was a cross-sectional analysis of retrospectively collected data from 72 sites providing both adult and paediatric ART as well as two providing adult ART only. All data were entered into and analysed using a WHO EWI data abstraction electronic tool.
RESULTS: Twenty-one percent of sites providing adult and 4.2% of sites providing paediatric ART managed to meet the target for on time pill pick up. Retention in care indicator was met by 48.7% (95% CI: 36.9-60.6) of sites. ARV stock-outs occurred in 81.1% (95% CI: 70-89.3) adult sites and 63.9% (95% CI: 50-78.6) paediatric sites. ARVs were appropriately dispensed by 86.5% (95% CI: 75.6-93.3) of adult sites and 84.7% (95% CI: 74.3-92.1) of paediatric sites.
CONCLUSIONS: Most sites had low performance in many indicators in this survey and failed to meet the recommended targets. Some policies such as the current buffer stock and storage outside Harare should be revised in order to improve site access to ARVs. The country should prioritize the provision of viral load testing services in all provinces. The electronic patient management system should be rolled out to all ART sites to improve patient tracking and monitoring by sites.

Entities:  

Keywords:  Early warning indicators; Retention; Stock-outs; Zimbabwe

Year:  2016        PMID: 29862318      PMCID: PMC5983043          DOI: 10.5430/jer.v2n2p85

Source DB:  PubMed          Journal:  J Epidemiol Res


  16 in total

1.  Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.

Authors:  M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Authors:  Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Authors:  Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

4.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Authors:  Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

5.  HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.

Authors:  Diane E Bennett; Michael R Jordan; Silvia Bertagnolio; Steven Y Hong; Giovanni Ravasi; James H McMahon; Ahmed Saadani; Karen F Kelley
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

6.  Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

Authors:  David R Bangsberg; Edward P Acosta; Reena Gupta; David Guzman; Elise D Riley; P Richard Harrigan; Neil Parkin; Steven G Deeks
Journal:  AIDS       Date:  2006-01-09       Impact factor: 4.177

Review 7.  Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges.

Authors:  Marco Vitoria; Stefano Vella; Nathan Ford
Journal:  Curr Opin HIV AIDS       Date:  2013-01       Impact factor: 4.283

8.  Early warning indicators for HIV drug resistance in Cameroon during the year 2010.

Authors:  Serge C Billong; Joseph Fokam; Armand S Nkwescheu; Etienne Kembou; Pascal Milenge; Zephirin Tsomo; Grace Ngute Dion; Avelin F Aghokeng; Eitel N Mpoudi; Peter M Ndumbe; Vittorio Colizzi; Jean B Elat Nfetam
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

9.  Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013.

Authors:  Yibeltal Assefa; Achamyeleh Alebachew; Meskele Lera; Lut Lynen; Edwin Wouters; Wim Van Damme
Journal:  Global Health       Date:  2014-05-27       Impact factor: 4.185

10.  HIV drug resistance early warning indicators in namibia with updated World Health Organization guidance.

Authors:  Anna Jonas; Victor Sumbi; Samson Mwinga; Michael DeKlerk; Francina Tjituka; Scott Penney; Michael R Jordan; Tiruneh Desta; Alice M Tang; Steven Y Hong
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

View more
  1 in total

1.  A longitudinal review of national HIV policy and progress made in health facility implementation in Eastern Zimbabwe.

Authors:  Malebogo Tlhajoane; Tidings Masoka; Edith Mpandaguta; Rebecca Rhead; Kathryn Church; Alison Wringe; Noah Kadzura; Nimalan Arinaminpathy; Constance Nyamukapa; Nadine Schur; Owen Mugurungi; Morten Skovdal; Jeffrey W Eaton; Simon Gregson
Journal:  Health Res Policy Syst       Date:  2018-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.